Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (CDNA) has launched a next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, aimed at supporting research in vaccine and drug development. This HLA typing service, powered by AlloSeq Tx17, offers superior gene content and efficient testing capabilities. The service has already been engaged by a top global pharmaceutical company. CareDx is focusing on expanding its global presence and enhancing support for drug development research, enhancing patient care worldwide.
CareDx (Nasdaq: CDNA) will participate in the National Kidney Foundation's 2021 Spring Clinical Meetings from April 6-10, 2021. The company will host a virtual exhibitor showcase titled “Next Generation Care for Kidney Transplant Patients” on April 6, featuring experts like Dr. Christopher Boshkos and Dr. Matthew Weir discussing AlloSure, a standard for kidney transplant surveillance. Additionally, CareDx will sponsor a CME program on April 8 focusing on acute rejection in kidney transplantation, showcasing leading medical professionals' insights.
CareDx, a precision medicine company, has recently announced key leadership appointments to bolster its growth and enhance the patient experience in transplant healthcare. Reg Seeto, President and CEO, emphasized a commitment to innovation and patient-focused integrated digital offerings. New hires include Titte R. Srinivas, M.D., as VP of Digital Development, and Steven Stone, Ph.D., as VP of KidneyCare. Promotions include Marica Grskovic, Ph.D., to VP of Cell Transplant Therapy, reflecting the company’s dedication to improving transplant patient care.
CareDx, Inc. (Nasdaq: CDNA) announced efforts to raise awareness for Vir Biotechnology’s COMET-ICE study, evaluating the monoclonal antibody VIR-7831 for early COVID-19 treatment in high-risk adults. The trial, which focuses on the immune-compromised transplant patient population, was halted for enrollment following recommendations from an Independent Data Monitoring Committee due to significant efficacy. CareDx aims to facilitate patient access to clinical trials, providing additional treatment options beyond vaccines for vulnerable transplant patients.
CareDx, a precision medicine company focused on transplant solutions, has acquired BFS Molecular, a software firm specializing in NGS-based patient testing. This acquisition strengthens CareDx's portfolio with advanced software and algorithm development capabilities for transplant surveillance products like AlloSeq cfDNA and AlloSeq HCT. Tim Hague, the former CEO of BFS Molecular, will join CareDx as Vice President of Global Lab Products Software, enhancing their bioinformatics expertise and presence in Europe. CareDx aims to improve the transplant patient journey through this strategic acquisition.
CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Ankur Dhingra as the new Chief Financial Officer, effective March 25, 2021. Dhingra brings over 25 years of finance and accounting experience, previously serving as Vice President of Investor Relations at Agilent Technologies. CEO Reg Seeto expressed confidence that Dhingra's expertise will enhance operational growth and financial performance at CareDx. The company focuses on precision medicine for transplant patients, offering various healthcare solutions throughout the entire transplant journey.
CareDx, Inc. (Nasdaq: CDNA) announced the acquisition of TX Services, LLC, including its TX Connect service, which adds 19,000 patient referrals for kidney transplants. This cloud-based service allows nephrologists and dialysis centers to streamline electronic referrals to transplant programs. The integration enhances CareDx's pre-transplant offerings, complementing existing services like XynManagement. CEO Reg Seeto highlighted that TX Connect aids in helping more kidney patients get on transplant waitlists, enhancing patient care through better communication and management across the healthcare continuum.
CareDx, a precision medicine company, reported strong financial results for Q4 and full-year 2020. Q4 revenue reached $58.6 million, a 64% increase year-over-year, contributing to a record $192.2 million for the full year, up 51% from 2019. The company achieved a non-GAAP net income of $4.3 million in Q4 and $11.3 million for the full year. Despite a GAAP net loss of $3.5 million in Q4, the results signal a positive trajectory. Additionally, CareDx has provided over 79,000 patient results in 2020 and received Medicare reimbursement for AlloSure Heart.
CareDx, Inc. (Nasdaq: CDNA) is set to showcase its AlloSure donor-derived cell-free DNA (dd-cfDNA) technology at the Cutting Edge of Transplantation Meeting, occurring from February 25-27, 2021. Key presentations will include the ADMIRAL study, highlighting AlloSure's effectiveness in detecting allograft rejection among over 1,000 patients across various transplant centers. Additional research will be presented on the clinical applications of dd-cfDNA in real-life settings, including case studies and its relevance during the COVID-19 pandemic. CEO Reg Seeto emphasized the significance of these findings for post-transplant patient care.
CareDx, Inc. (CDNA) will release its financial results for the fourth quarter and full year 2020 after market close on February 24, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, with dial-in numbers available for domestic and international callers. CareDx is renowned for its precision medicine solutions for transplant patients, offering testing services and digital healthcare solutions.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
